NO306761B1 - Fremgangsmåte for fremstilling av et blodplateavledet produkt - Google Patents

Fremgangsmåte for fremstilling av et blodplateavledet produkt Download PDF

Info

Publication number: NO306761B1
Authority: NO; Norway
Prior art keywords: platelet; platelets; preparation; platelet membrane; microparticles
Prior art date: 1989-04-14

Application number

NO914024A

Other languages

English (en)

Norwegian (no)

Other versions

NO914024D0 (no

NO914024L (no

Inventor

Francis Chao

Original Assignee

Prp Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-14

Filing date

1991-10-14

Publication date

1999-12-20

1991-10-14 Application filed by Prp Inc filed Critical Prp Inc

1991-10-14 Publication of NO914024D0 publication Critical patent/NO914024D0/no

1991-10-14 Publication of NO914024L publication Critical patent/NO914024L/no

1999-12-20 Publication of NO306761B1 publication Critical patent/NO306761B1/no

Links

238000000034 method Methods 0.000 title claims description 19
238000002360 preparation method Methods 0.000 claims description 54
239000012528 membrane Substances 0.000 claims description 49
239000011859 microparticle Substances 0.000 claims description 48
239000000047 product Substances 0.000 claims description 26
230000002947 procoagulating effect Effects 0.000 claims description 21
239000012634 fragment Substances 0.000 claims description 19
238000010438 heat treatment Methods 0.000 claims description 16
241000700605 Viruses Species 0.000 claims description 13
238000009210 therapy by ultrasound Methods 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
239000002244 precipitate Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 5
238000000265 homogenisation Methods 0.000 claims description 4
239000007858 starting material Substances 0.000 claims description 3
210000001772 blood platelet Anatomy 0.000 description 190
230000000740 bleeding effect Effects 0.000 description 35
206010043554 thrombocytopenia Diseases 0.000 description 30
230000000694 effects Effects 0.000 description 26
241000283973 Oryctolagus cuniculus Species 0.000 description 20
241001465754 Metazoa Species 0.000 description 17
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
108010000020 Platelet Factor 3 Proteins 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
239000000463 material Substances 0.000 description 11
239000000725 suspension Substances 0.000 description 11
239000006166 lysate Substances 0.000 description 10
239000008188 pellet Substances 0.000 description 10
108090000190 Thrombin Proteins 0.000 description 9
230000037396 body weight Effects 0.000 description 9
229960004072 thrombin Drugs 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 8
239000000243 solution Substances 0.000 description 8
239000000427 antigen Substances 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
238000011109 contamination Methods 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
230000002439 hemostatic effect Effects 0.000 description 6
150000003904 phospholipids Chemical class 0.000 description 6
239000002504 physiological saline solution Substances 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
238000003556 assay Methods 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
230000002779 inactivation Effects 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
238000010257 thawing Methods 0.000 description 5
206010060935 Alloimmunisation Diseases 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
102000012750 Membrane Glycoproteins Human genes 0.000 description 4
108010090054 Membrane Glycoproteins Proteins 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
238000010586 diagram Methods 0.000 description 4
239000012467 final product Substances 0.000 description 4
238000007710 freezing Methods 0.000 description 4
230000008014 freezing Effects 0.000 description 4
230000023597 hemostasis Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
229940090044 injection Drugs 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
229960002918 doxorubicin hydrochloride Drugs 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
239000003805 procoagulant Substances 0.000 description 3
229940076279 serotonin Drugs 0.000 description 3
238000003860 storage Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000003634 thrombocyte concentrate Substances 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
102000011786 HLA-A Antigens Human genes 0.000 description 2
108010075704 HLA-A Antigens Proteins 0.000 description 2
102000006390 HLA-B Antigens Human genes 0.000 description 2
108010058607 HLA-B Antigens Proteins 0.000 description 2
101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 2
102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 2
241000271897 Viperidae Species 0.000 description 2
230000000961 alloantigen Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000012620 biological material Substances 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
229960002092 busulfan Drugs 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
238000012937 correction Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
239000012502 diagnostic product Substances 0.000 description 2
229940035756 doxorubicin injection Drugs 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
239000002821 viper venom Substances 0.000 description 2
208000030507 AIDS Diseases 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
-1 UV light Substances 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000002617 apheresis Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000003582 thrombocytopenic effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000002435 venom Substances 0.000 description 1
210000001048 venom Anatomy 0.000 description 1
231100000611 venom Toxicity 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Cell Biology (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Epidemiology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Manufacturing Of Micro-Capsules (AREA)
Peptides Or Proteins (AREA)
Separation Using Semi-Permeable Membranes (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

NO914024A 1989-04-14 1991-10-14 Fremgangsmåte for fremstilling av et blodplateavledet produkt NO306761B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/337,916 US5185160A (en)	1984-06-21	1989-04-14	Platelet membrane microvesicles
PCT/US1990/001989 WO1990012581A1 (fr)	1989-04-14	1990-04-12	Microparticules de membranes de plaquettes sanguines

Publications (3)

Publication Number	Publication Date
NO914024D0 NO914024D0 (no)	1991-10-14
NO914024L NO914024L (no)	1991-10-14
NO306761B1 true NO306761B1 (no)	1999-12-20

Family

ID=23322568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO914024A NO306761B1 (no)	1989-04-14	1991-10-14	Fremgangsmåte for fremstilling av et blodplateavledet produkt

Country Status (16)

Country	Link
US (1)	US5185160A (fr)
EP (2)	EP0467991B1 (fr)
JP (1)	JP2972329B2 (fr)
KR (1)	KR0162094B1 (fr)
AT (1)	ATE169501T1 (fr)
AU (2)	AU649398B2 (fr)
CA (1)	CA2051659C (fr)
DE (1)	DE69032559T2 (fr)
DK (1)	DK0467991T3 (fr)
ES (1)	ES2118721T3 (fr)
FI (1)	FI107702B (fr)
GR (1)	GR1001172B (fr)
HU (1)	HU214884B (fr)
IE (1)	IE990035A1 (fr)
NO (1)	NO306761B1 (fr)
WO (1)	WO1990012581A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5428008A (en) *	1989-04-14	1995-06-27	Prp, Inc.	Therapeutic composition of micellar structures capable of promoting hemotasis
US5332578A (en) *	1989-04-14	1994-07-26	Prp, Inc.	Platelet membrane microparticles
US6187572B1 (en)	1990-04-16	2001-02-13	Baxter International Inc.	Method of inactivation of viral and bacterial blood contaminants
US5358844A (en) *	1993-02-18	1994-10-25	Brigham And Women's Hospital, Inc.	Preservation of blood platelets
US5462752A (en) *	1994-07-28	1995-10-31	Prp, Inc.	Inhibition of platelet binding
AT407484B (de) *	1997-11-12	2001-03-26	Bio Prod & Bio Eng Ag	Arzneimittel zur förderung der wundheilung
EP1351697B1 (fr) *	2001-01-18	2013-10-30	Georg Watzek	Agent pharmaceutique destine a favoriser la regeneration des tissus
US20050191286A1 (en) *	2004-02-09	2005-09-01	Gandy James B.	Lyophilized platelet rich plasma for the use in wound healing (chronic or acute) and bone or tissue grafts or repair
US20060004189A1 (en) *	2004-07-02	2006-01-05	James Gandy	Compositions for treating wounds and processes for their preparation
US20060142198A1 (en) *	2004-07-02	2006-06-29	Wound Care Partners Llc	Compositions for treating wounds and processes for their preparation
WO2006060779A2 (fr) *	2004-12-03	2006-06-08	Case Western Reserve University	Nouvelles methodes, nouvelles compositions et nouveaux dispositifs induisant une neovascularisation
DE102006045550A1 (de) *	2006-09-25	2008-04-03	Dade Behring Marburg Gmbh	Verfahren zur Herstellung von agglutionationsfähigen Thrombozytenfragmenten und deren Verwendung
ES2982461T3 (es)	2008-09-16	2024-10-16	Mayo Found Medical Education & Res	Composiciones que contienen contenido plaquetario
US11891620B2 (en)	2014-05-16	2024-02-06	Mayo Foundation For Medical Education And Research	Cell culture media compositions for primary cells
EP3265116B1 (fr) *	2015-03-04	2021-06-02	University of Rochester	Application topique et systémique de microparticules plaquettaires pour traiter le saignement chez des patients souffrant d'un traumatisme
EP3267965A4 (fr) *	2015-03-11	2018-11-14	Atta Behfar	Technologie d'administration d'exosomes
WO2016205144A1 (fr) *	2015-06-14	2016-12-22	Bluecircle Therapeutics, Inc.	Compositions de théranostiques dérivés de plaquettes et leurs utilisations
US11767511B2 (en)	2018-11-30	2023-09-26	Cellphire, Inc.	Platelets as delivery agents
EP3887404A4 (fr)	2018-11-30	2022-11-02	Cellphire, Inc.	Plaquettes chargées d'agents anticancéreux
AU2020267368B2 (en)	2019-05-03	2023-05-04	Cellphire, Inc.	Materials and methods for producing blood products
EP4013496A4 (fr)	2019-08-16	2023-10-18	Cellphire Inc.	Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire
CA3170201A1 (fr)	2020-02-04	2021-08-12	Cellphire, Inc.	Procedes de traitement de l'hemophilie congenitale avec des plaquettes chargees d'un anti-fibrinolytique
WO2021232015A1 (fr) *	2020-05-15	2021-11-18	Cellphire, Inc.	Vésicules extracellulaires dérivées de plaquettes
TW202245814A (zh)	2021-02-17	2022-12-01	美商賽菲爾公司	用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物
WO2024192173A1 (fr) *	2023-03-14	2024-09-19	Cellphire, Inc.	Compositions dérivées de plaquettes caractérisées par hla, et méthodes de fabrication, de sélection et d'utilisation de telles compositions
WO2024229305A1 (fr) *	2023-05-03	2024-11-07	Cellphire, Inc.	Compositions de dérivé de plaquettes destinées à être utilisées dans la régulation du saignement chez un sujet
CN117643621B (zh) *	2023-10-27	2024-07-02	江苏省人民医院（南京医科大学第一附属医院）	一种溶栓药PLT-r-SAK及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4994438A (en) *	1981-11-02	1991-02-19	Cedars Sinai Medical Center	Heat treatment of lyophilized plasma fractions
US4456590B2 (en) *	1981-11-02	1989-05-30		Heat treatment of lyphilized blood clotting factor viii concentrate
US4540573A (en) *	1983-07-14	1985-09-10	New York Blood Center, Inc.	Undenatured virus-free biologically active protein derivatives
US4760131A (en) *	1986-04-23	1988-07-26	Collagen Corporation	Wound-healing composition
US4764463A (en) *	1986-10-30	1988-08-16	The University Of Tennessee Research Corporation	Platelet cyropreservation
US4753797A (en) *	1987-06-24	1988-06-28	Miles Laboratories, Inc.	Enhancing platelet morphology prior to patient use

1989
- 1989-04-14 US US07/337,916 patent/US5185160A/en not_active Expired - Fee Related
1990
- 1990-04-12 WO PCT/US1990/001989 patent/WO1990012581A1/fr not_active Ceased
- 1990-04-12 CA CA002051659A patent/CA2051659C/fr not_active Expired - Fee Related
- 1990-04-12 AT AT90908046T patent/ATE169501T1/de not_active IP Right Cessation
- 1990-04-12 ES ES90908046T patent/ES2118721T3/es not_active Expired - Lifetime
- 1990-04-12 AU AU55388/90A patent/AU649398B2/en not_active Ceased
- 1990-04-12 DK DK90908046T patent/DK0467991T3/da active
- 1990-04-12 EP EP90908046A patent/EP0467991B1/fr not_active Expired - Lifetime
- 1990-04-12 IE IE19990035A patent/IE990035A1/en unknown
- 1990-04-12 EP EP97113637A patent/EP0815866A3/fr not_active Ceased
- 1990-04-12 KR KR1019910701331A patent/KR0162094B1/ko not_active Expired - Fee Related
- 1990-04-12 JP JP2506787A patent/JP2972329B2/ja not_active Expired - Lifetime
- 1990-04-12 DE DE69032559T patent/DE69032559T2/de not_active Expired - Fee Related
- 1990-04-12 HU HU374/90A patent/HU214884B/hu not_active IP Right Cessation
- 1990-04-17 GR GR900100286A patent/GR1001172B/el unknown
1991
- 1991-10-11 FI FI914819A patent/FI107702B/fi active
- 1991-10-14 NO NO914024A patent/NO306761B1/no not_active IP Right Cessation
1993
- 1993-07-15 AU AU41950/93A patent/AU652317B2/en not_active Ceased

Also Published As

Publication number	Publication date
FI914819A0 (fi)	1991-10-11
JPH04506451A (ja)	1992-11-12
AU5538890A (en)	1990-11-16
DE69032559D1 (de)	1998-09-17
EP0815866A2 (fr)	1998-01-07
GR900100286A (en)	1991-09-27
EP0467991B1 (fr)	1998-08-12
EP0467991A1 (fr)	1992-01-29
AU649398B2 (en)	1994-05-26
DK0467991T3 (da)	1999-02-01
EP0467991A4 (en)	1993-01-07
CA2051659C (fr)	2001-08-07
AU652317B2 (en)	1994-08-18
HU903374D0 (en)	1991-12-30
HUT61200A (en)	1992-12-28
CA2051659A1 (fr)	1990-10-15
GR1001172B (el)	1993-06-07
ATE169501T1 (de)	1998-08-15
EP0815866A3 (fr)	1998-08-12
JP2972329B2 (ja)	1999-11-08
WO1990012581A1 (fr)	1990-11-01
KR920700661A (ko)	1992-08-10
AU4195093A (en)	1993-10-07
NO914024D0 (no)	1991-10-14
NO914024L (no)	1991-10-14
IE990035A1 (en)	2000-11-01
KR0162094B1 (ko)	1998-12-01
ES2118721T3 (es)	1998-10-01
HU214884B (hu)	2000-03-28
DE69032559T2 (de)	1999-01-07
FI107702B (fi)	2001-09-28
US5185160A (en)	1993-02-09

Legal Events

Date	Code	Title	Description
2002-12-09	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN OCTOBER 2002

Publication	Publication Date	Title
NO306761B1 (no)	1999-12-20	Fremgangsmåte for fremstilling av et blodplateavledet produkt
US5332578A (en)	1994-07-26	Platelet membrane microparticles
US5844098A (en)	1998-12-01	Reconstituted platelet membrane vesicles
US5462752A (en)	1995-10-31	Inhibition of platelet binding
US8105632B2 (en)	2012-01-31	Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders
Breen et al.	1969	Prothrombin concentrates in treatment of Christmas disease and allied disorders
US20260061003A1 (en)	2026-03-05	Platelet-rich plasma compositions, preparation, and uses thereof
MALLORY et al.	1976	The use of banked autologous blood in total hip replacement surgery.
US20180369346A1 (en)	2018-12-27	Methods, compositions and kits for reducing tissue adhesions
Wiernik et al.	1969	Pulmonary embolus in acute myelocytic leukemia
Smith et al.	1984	Preparation of pooled cryoprecipitate for treatment of hemophilia A in a home care program
HU211345A9 (hu)	1995-11-28	Vérlemezke-membrán mikrorészecskék Az átmeneti oltalom az 1-14. igénypontokra vonatkozik.
Gelinas et al.	2001	Thrombocytopenia and critical care medicine
Marks et al.	2026	Production and Storage of Blood Components
Sarkodee-Adoo et al.	1996	Platelet transfusion support for patients with cancer and hematologic malignancies
Perkins	1966	Plasmapheresis of the patient as a method for achieving effective levels of plasma coagulation factors using fresh frozen plasma
Harrison et al.	1992	Special issues in transfusion medicine
BLOOD	0	RATIONAL USE OF BLOOD AND BLOOD PRODUCTS
Conlan et al.	2002	Pathogen Inactivated Blood Components: Advancing from Theory to Practice